FY2027 EPS Estimates for Insulet Lifted by Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Equities researchers at Leerink Partnrs lifted their FY2027 earnings per share estimates for shares of Insulet in a research note issued to investors on Thursday, May 8th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings per share of $7.10 for the year, up from their previous estimate of $6.89. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet’s FY2028 earnings at $8.86 EPS and FY2029 earnings at $10.58 EPS.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. During the same period last year, the company posted $0.73 EPS. The business’s quarterly revenue was up 28.8% on a year-over-year basis.

Several other research firms have also commented on PODD. Wolfe Research lowered Insulet from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, April 29th. StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Stifel Nicolaus lifted their target price on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Oppenheimer lifted their target price on Insulet from $312.00 to $324.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Royal Bank of Canada assumed coverage on Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $303.81.

Insulet Trading Up 20.8%

NASDAQ:PODD opened at $310.42 on Monday. The business’s 50-day moving average is $257.45 and its two-hundred day moving average is $263.88. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 12 month low of $160.19 and a 12 month high of $312.80. The firm has a market capitalization of $21.84 billion, a PE ratio of 53.61, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26.

Insider Buying and Selling at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.47% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently made changes to their positions in PODD. Principal Financial Group Inc. raised its holdings in shares of Insulet by 4.0% during the third quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier’s stock valued at $20,065,000 after buying an additional 3,355 shares during the last quarter. Nordea Investment Management AB raised its holdings in Insulet by 6.3% during the fourth quarter. Nordea Investment Management AB now owns 6,078 shares of the medical instruments supplier’s stock worth $1,598,000 after purchasing an additional 359 shares in the last quarter. Graypoint LLC raised its holdings in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares in the last quarter. Czech National Bank raised its holdings in Insulet by 6.5% during the fourth quarter. Czech National Bank now owns 15,209 shares of the medical instruments supplier’s stock worth $3,971,000 after purchasing an additional 926 shares in the last quarter. Finally, CHICAGO TRUST Co NA bought a new stake in Insulet during the fourth quarter worth approximately $294,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.